<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="nihpa" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC1459289/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>Pharmacokinetic interaction between nelfinavir and
pravastatin in HIV-seronegative volunteers: ACTG Study
A5108</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC1459289/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"AIDS (London, England)" />
<meta name="citation_title" content=
"Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108" />
<meta name="citation_authors" content=
"Judith A. Aberg, Susan L. Rosenkranz, Carl J. Fichtenbaum, Beverly L. Alston, Susan W. Brobst, Yoninah Segal, John G. Gerber, for the ACTG A5108 team" />
<meta name="citation_date" content="21 March 2006" />
<meta name="citation_issue" content="5" />
<meta name="citation_volume" content="20" />
<meta name="citation_firstpage" content="725" />
<meta name="citation_doi" content=
"10.1097/01.aids.0000216373.53819.92" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC1459289/?report=abstract" />
<meta name="citation_pmid" content="16514303" />
<meta name="DC.Title" content=
"Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="NIH Public Access" />
<meta name="DC.Contributor" content="Judith A. Aberg" />
<meta name="DC.Contributor" content="Susan L. Rosenkranz" />
<meta name="DC.Contributor" content="Carl J. Fichtenbaum" />
<meta name="DC.Contributor" content="Beverly L. Alston" />
<meta name="DC.Contributor" content="Susan W. Brobst" />
<meta name="DC.Contributor" content="Yoninah Segal" />
<meta name="DC.Contributor" content="John G. Gerber" />
<meta name="DC.Contributor" content="for the ACTG A5108 team" />
<meta name="DC.Date" content="2006 Mar 21" />
<meta name="DC.Identifier" content=
"10.1097/01.aids.0000216373.53819.92" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"Background: Nelfinavir, an HIV protease inhibitor with numerous drug–drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia.Objective: To examine the effect of nelfinavir ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459289/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC1459289/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC1459289/pdf/nihms-8950.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"F4FC2520762FFE010000000000F22EFE" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="article-entrez-filter"><a href=
"/pmc/?term=hhs%20author%20manuscript[filter]&amp;cmd=search&amp;EntrezSystem2.PEntrez.Pmc.Pmc_LimitsTab.LimitsOff=true"
class="navlink">HHS Author Manuscripts</a></li>
<li class="accid">PMC1459289</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-hhspa.png" alt=
"Logo of nihpa" usemap="#logo-imagemap" /><map id="logo-imagemap"
name="logo-imagemap">
<area shape="rect" coords="0,57,255,75" alt=
"About Author manuscripts" title="About Author manuscripts" href=
"http://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref=
"http://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" />
<area shape="rect" coords="256,57,500,75" alt="Submit a manuscript"
title="Submit a manuscript" href="http://www.nihms.nih.gov/" ref=
"reftype=publisher&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal"
target="pmc_ext" />
<area shape="rect" coords="0,0,499,74" alt=
"HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;"
title=
"HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;"
href="http://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref=
"reftype=publisher&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal"
target="pmc_ext" /></map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>AIDS. Author manuscript; available in PMC 2006 May 11.</div>
<div>Published in final edited form as:</div>
<div style="margin-left:1em">
<div class="fm-vol-iss-date"><a href=
"/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=16514303"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access&amp;rendering-type=normal">
<span class="cit">AIDS. 2006 Mar 21; 20(5):
725–729.</span></a></div>
<span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1097%2F01.aids.0000216373.53819.92" target=
"pmc_ext" ref=
"reftype=other&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1097/01.aids.0000216373.53819.92</a></span></div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC1459289</span></div>
<div class="fm-citation-manuscriptid"><span class=
"fm-citation-ids-label">NIHMSID:</span>
<span>NIHMS8950</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">Pharmacokinetic interaction between
nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG
Study A5108</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Aberg%20JA%5Bauth%5D">Judith A.
Aberg</a>,<sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt=
"corresponding author" /></sup><sup>a</sup> <a href=
"/pubmed/?term=Rosenkranz%20SL%5Bauth%5D">Susan L.
Rosenkranz</a>,<sup>b</sup> <a href=
"/pubmed/?term=Fichtenbaum%20CJ%5Bauth%5D">Carl J.
Fichtenbaum</a>,<sup>c</sup> <a href=
"/pubmed/?term=Alston%20BL%5Bauth%5D">Beverly L.
Alston</a>,<sup>d</sup> <a href=
"/pubmed/?term=Brobst%20SW%5Bauth%5D">Susan W.
Brobst</a>,<sup>e</sup> <a href=
"/pubmed/?term=Segal%20Y%5Bauth%5D">Yoninah Segal</a>,<sup>b</sup>
<a href="/pubmed/?term=Gerber%20JG%5Bauth%5D">John G.
Gerber</a>,<sup>f</sup> and for the ACTG A5108
team<sup>*</sup></div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id1040971_ai" style="display:none">
<div class="fm-affl" lang="en"><sup>a</sup>From the New York
University, New York, New York</div>
<div class="fm-affl" lang="en"><sup>b</sup>From the Harvard School
of Public Health, Boston, Massachusetts</div>
<div class="fm-affl" lang="en"><sup>c</sup>From the University of
Cincinnati, Cincinnati, Ohio</div>
<div class="fm-affl" lang="en"><sup>d</sup>From the National
Institute of Allergy and Infectious Diseases, National Institutes
of Health, Bethesda, Maryland</div>
<div class="fm-affl" lang="en"><sup>e</sup>From the Social and
Scientific Systems, Inc., Silver Spring, Maryland</div>
<div class="fm-affl" lang="en"><sup>f</sup>From the University of
Colorado Health Sciences Center, Denver, Colorado, USA</div>
<div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt=
"corresponding author" /></sup>Corresponding author.</div>
<div id="FN1"><sup>*</sup>See <a href="#APP1" rid="APP1" class=
" app">Appendix</a>.</div>
<div id="CR1">Correspondence to Dr J. Aberg, New York University,
Bellevue C and D Building, Room 558, 550 First Ave, New York, New
York 10016–6481, USA. E-mail: <a href="mailto:dev@null" data-email=
"ude.uyn.dem@greba.htiduj" class=
"oemail">ude.uyn.dem@greba.htiduj</a></div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id1040971_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id1040971_cpl">Copyright and License
information <span>►</span></a></div>
<div class="fm-article-notes fm-panel half_rhythm"></div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id1040971_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright notice</a> and <a href=
"/About/disclaimer.html">Disclaimer</a></div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>The publisher's final edited version of this article is
available at <a href=
"/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=16514303"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access&amp;rendering-type=normal">
AIDS</a></div>
<div>See other articles in PMC that <a href=
"/pmc/articles/PMC1459289/citedby/">cite</a> the published
article.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid405344" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid405344title">
Abstract</h2>
<!--article-meta-->
<div>
<p id="P2" class="p p-first"><strong>Background:</strong>
Nelfinavir, an HIV protease inhibitor with numerous drug–drug
interactions, is associated with dyslipidemia. Pravastatin is the
preferred statin prescribed for HIV-associated dyslipidemia.</p>
<p id="P3"><strong>Objective:</strong> To examine the effect of
nelfinavir on pravastatin pharmacokinetics.</p>
<p id="P4"><strong>Design:</strong> Open-label study in healthy
HIV-seronegative adults conducted at the AIDS Clinical Trials Group
sites in the United States.</p>
<p id="P5"><strong>Methods:</strong> Subjects received pravastatin
40 mg daily and underwent intensive sampling for pharmacokinetics
on day 3. Subjects took only nelfinavir 1250 mg twice daily on days
4–12. On days 13–15, subjects continued nelfinavir and reinitiated
pravastatin. Plasma samples were collected over 24 h for the
calculation of pravastatin area under the concentration–time curve
for 0–24 h on days 3 and 16.</p>
<p id="P6"><strong>Results:</strong> Data from 14 subjects with
complete pharmacokinetic samples were available for analysis. The
median within-subject percentage change in pravastatin AUC was a
decrease of 46.5%. Pravastatin maximum plasma concentrations were
also lower when pravastatin was administered with nelfinavir.
Median values for the maximum plasma concentrations were 27.9 and
12.4 ng/ml for days 3 and 16, respectively, and the median
within-subject decrease was 40.1%.</p>
<p id="P7" class="p p-last"><strong>Conclusions:</strong>
Coadministration of pravastatin and nelfinavir led to a substantial
reduction in pravastatin plasma concentrations. Higher doses of
pravastatin may need to be prescribed in order to achieve optimal
lipid-lowering activity.</p>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">HIV infection, statins, pravastatin,
nelfinavir, drug interactions</span></div>
</div>
<div id="S1" class="tsec sec">
<h2 class="head no_bottom_margin" id="S1title">Introduction</h2>
<p id="P8" class="p p-first">Nelfinavir (NFV) is an HIV protease
inhibitor (PI) that has demonstrated numerous drug–drug
interactions and is also associated with dyslipidemia, which may
require lipid-lowering therapy [<a href="#R1" rid="R1" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744563">1</a>]. This therapy uses
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors known as
statins. In a previous study, we demonstrated that simvastatin
should not be used with ritonavir/saquinavir because of the large
increases in plasma concentrations from inhibition of CYP3A4
metabolism [<a href="#R2" rid="R2" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744562">2</a>]. Similarly, atorvastatin exposure was also
increased by CYP3A4 inhibitors [<a href="#R2" rid="R2" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744574">2</a>,<a href="#R3" rid="R3" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744572">3</a>]. Pravastatin was likely to be safe when
coadministered with ritonavir/saquinavir because, instead of an
increase, we observed a 50% decrease in pravastatin area under the
concentration–time curve (AUC). Although we also showed that
pravastatin did not alter NFV pharmacokinetics, we did not examine
the effect of NFV on pravastatin pharmacokinetics. More recently,
we have demonstrated that a non-nucleoside reverse transcriptase
inhibitor efavirenz, which is a CYP3A4 inducer, also reduced the
plasma exposure of pravastatin [<a href="#R4" rid="R4" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_310856341">4</a>].</p>
<p id="P9" class="p p-last">The mechanism by which these drugs
reduce plasma exposure to pravastatin is unknown, but this
drug–drug interaction is of concern because a reduction in
pravastatin plasma concentration may adversely affect the drug's
ability to lower serum cholesterol effectively. NFV is one of the
few PI drugs in clinical use that is not usually combined with
ritonavir, but NFV has a similar effect on the CYP enzymes as
ritonavir in that it is an inhibitor of CYP3A4 but an inducer of
other CYP isoforms. Pravastatin metabolism is complex, utilizing
both oxidative and conjugative enzymes for elimination, but CYP3A4
is not a significant enzyme in its metabolism. This study examines
the hypothesis that NFV would have a similar effect on pravastatin
pharmacokinetics as ritonavir/saquinavir.</p>
</div>
<div id="S2" class="tsec sec">
<h2 class="head no_bottom_margin" id="S2title">Methods</h2>
<p id="P10" class="p p-first">The AIDS Clinical Trials Group (ACTG)
study A5108 was a phase I, open-label, multiple-dose,
pharmacokinetic drug interaction study. The primary objectives were
to examine the effect of efavirenz on the pharmacokinetics of
pravastatin, atorvastatin, and simvastatin and the effect of NFV on
the pharmacokinetics of pravastatin. The efavirenz–statin
interactions were recently published [<a href="#R4" rid="R4" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_310856342">4</a>]. The data presented here address the
effect of NFVon the pharmacokinetics of pravastatin. At the time of
this study design, NFV was the most commonly prescribed PI in
antiretroviral-naive patients.</p>
<div id="S3" class="sec">
<h3>Subjects</h3>
<p id="P11" class="p p-first-last">Healthy HIV-seronegative
volunteers were recruited. The planned sample size was 14 subjects.
Subjects who did not complete both pharmacokinetics evaluations
were replaced. Subjects were accrued to the NFV arm from August
through December 2001.</p>
</div>
<div id="S4" class="sec">
<h3>Study design</h3>
<p id="P12" class="p p-first">Subjects self-administered
pravastatin 40 mg daily in the morning for the first 3 days and on
the fourth day pravastatin was administered under observation.
Blood samples were obtained before drug administration as well as
0.5, 1, 2, 3, 4, 6, 8, 12, and 24 h after administration, for
pravastatin pharmacokinetics. On days 4 through 12, subjects took
NFV 1250 mg twice daily with meals. On days 13 through 15, subjects
continued NFV and restarted pravastatin with the morning dose of
NFV. On day 16, pravastatin and NFV doses were administered under
observation and samples were collected over 24 h for pravastatin
pharmacokinetics. Fasting serum total cholesterol, triglycerides,
and high density lipoprotein concentrations were measured at
baseline and on days 3, 13, and 16 using standard enzymatic assays.
Low density lipoprotein (LDL) was calculated using the Friedewald
equation. Adherence to study medications was measured using pill
counts and questionnaires.</p>
<p id="P13" class="p p-last">The human subjects committees of each
participating institution and the Division of AIDS, National
Institute of Allergy and Infectious Diseases, approved this study
and informed consent was obtained from all subjects.</p>
</div>
<div id="S5" class="sec">
<h3>Pravastatin assay</h3>
<p id="P14" class="p p-first-last">Samples for pravastatin plasma
concentrations were analyzed by Advion Biosciences Inc. (Ithaca,
New York, USA) as previously published [<a href="#R2" rid="R2"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744560">2</a>,<a href="#R4" rid="R4" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_310856340">4</a>].</p>
</div>
<div id="S6" class="sec sec-last">
<h3>Statistical analyses</h3>
<p id="P15" class="p p-first-last">The primary endpoint was the
pravastatin AUC from 0 to 24 h before and after coadministration of
NFV. Values for AUC were estimated according to the linear
trapezoidal rule [<a href="#R5" rid="R5" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_142744566">5</a>]
implemented using a macro written in SAS version 8.2 (SAS
Institute, Cary, North Carolina, USA). There was no extrapolation
beyond the dosing interval. The maximum plasma concentration
(<em>C</em><sub>max</sub>), defined as the maximum concentration
observed throughout the dosing interval, was also analyzed
statistically. If both the 0 and 24 h concentrations or if both
study day samples were unavailable for a given subject,
pharmacokinetics parameters were not calculated. The Wilcoxon
signed rank test [<a href="#R6" rid="R6" class=
" bibr popnode">6</a>], applied to within-subject differences in
AUC and in <em>C</em><sub>max</sub> values, was used to test the
null hypothesis of no difference in pravastatin exposure before
initiation of NFV versus after dosing to steady state. Values of
<em>C</em><sub>max</sub> were of interest because high plasma
concentrations of statins may be associated with toxicity [<a href=
"#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744567">7</a>]. Pravastatin exposure when taken with NFV
relative to when taken alone, median within-subject differences,
and 90% confidence intervals (CI) around geometric mean ratios are
reported. The last are recommended by the US Food and Drug
Administration to evaluate bioequivalence and drug interactions
[<a href="#R8" rid="R8" class=" bibr popnode">8</a>].</p>
</div>
</div>
<div id="S7" class="tsec sec">
<h2 class="head no_bottom_margin" id="S7title">Results</h2>
<p id="P16" class="p p-first">The study enrolled 18 subjects and
three discontinued for protocol-defined toxicities: one had grade 2
bilirubin elevation owing to previously undiagnosed Gilbert's
disease, one had grade 2 rash, and one had grade 2 creatine kinase
elevation. A fourth subject was non-compliant and was discontinued
from the study, leaving 14 subjects for whom pharmacokinetics data
were available on both study days. Among the 14 subjects, two had
grade 2 gastrointestinal complaints, one had grade 3 alanine
aminotransferase and grade 2 aspartate aminotransferase on day 16,
one had grade 2 fasting LDL elevation on day 13, and one had grade
2 skin eruptions on day 5 deemed unrelated to study medications.
The population characteristics were a median age of 29 years, 50%
women,79% white, 7% Latino, 7% African-American, and 7%
Asian/Pacific Islanders.</p>
<p id="P17">Plots of time-specific geometric mean concentrations of
pravastatin with and without NFV are shown in <a href=
"/pmc/articles/PMC1459289/figure/F1/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="F1" rid-ob="ob-F1"
co-legend-rid="lgnd_F1"><span>Fig. 1</span></a>. Median pravastatin
AUC values on days 3 and 16 were 86.5 and 46.8 ng·h/ml,
respectively (<a href="/pmc/articles/PMC1459289/table/T1/" target=
"true" class="fig-table-link table figpopup" rid-figpopup="T1"
rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). The
<em>P</em> value indicated a high level of statistical significance
for this difference. The median within-subject percentage change
was a decrease of 46.5%, and the 90% CI around the geometric mean
ratio was 0.46–0.65. Pravastatin <em>C</em><sub>max</sub> values
were also lower when pravastatin was administered with NFV. Median
<em>C</em><sub>max</sub> values were 27.9 and 12.4 ng/ml for days 3
and 16, respectively, and the median within-subject decrease was
40.1% (<a href="/pmc/articles/PMC1459289/table/T1/" target="true"
class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob=
"ob-T1" co-legend-rid=""><span>Table 1</span></a>).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="F1"
co-legend-rid="lgnd_F1"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1459289/figure/F1/" target="figure" rid-figpopup=
"F1" rid-ob="ob-F1"><img src=
"/pmc/articles/PMC1459289/bin/nihms-8950-0001.gif" class=
"small-thumb" alt="Fig. 1" title="Fig. 1" src-large=
"/pmc/articles/PMC1459289/bin/nihms-8950-0001.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_F1">
<div><a class="figpopup" href="/pmc/articles/PMC1459289/figure/F1/"
target="figure" rid-figpopup="F1" rid-ob="ob-F1">Fig. 1</a></div>
<!--caption a4-->
<div><span><strong>Geometric mean concentration of pravastatin at
each scheduled sample time and under the two dosing conditions,
without (day 3; —) and with (day 16; - - -) coadminstration of
nelfinavir.</strong> The 95% confidence intervals around the
geometric means are</span> <strong>...</strong></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"T1"><a href="/pmc/articles/PMC1459289/table/T1/" target="table"
rid-ob="ob-T1" rid-figpopup="T1" class=
"table img_link icnblk_img figpopup"><img alt="Table 1" title=
"Table 1" class="small-thumb" src=
"/pmc/articles/PMC1459289/table/T1/?report=thumb" src-large=
"/pmc/articles/PMC1459289/table/T1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href="/pmc/articles/PMC1459289/table/T1/"
target="table" rid-figpopup="T1" rid-ob="ob-T1">Table 1</a></div>
<!--caption a4-->
<div><span>Pravastatin pharmacokinetics parameters in the
nelfinavir arm (<em>n</em> =
14)<sup><sup>a</sup></sup>.</span></div>
</div>
</div>
<p id="P18" class="p p-last">The median within-subject change in
LDL, from baseline to day 13 (after 9 days of NFV administration),
was an increase of 105 mg/l (mean, 144; 95% CI, 65–223). This
change was significantly different from zero (<em>P</em> &lt;
0.001,Wilcoxon signed rank test). Median (mean) changes after 3
days of pravastatin administration were –200 mg/l (mean, –195) from
day 0 to day 3, and –155 mg/l (mean, –167) from day 13 to day 16,
for a median difference in within-subject response to pravastatin
of 28 mg/l (<em>P</em> = 0.436, Wilcoxon signed rank). The
percentage change in LDL during the two periods was also calculated
because the baseline LDL was increased by NFV. After 3 days of
pravastatin administration, the median changes were –19.7% (mean,
–19.8) from day 0 to day 3, and –11.4% (mean, –14.2) from day 13 to
day 16, for a median difference in within-subject response to
pravastatin of 6.7% (mean, 5.5). This difference was not
statistically significant (<em>P</em> = 0.104, Wilcoxon signed rank
test).</p>
</div>
<div id="S8" class="tsec sec">
<h2 class="head no_bottom_margin" id="S8title">Discussion</h2>
<p id="P19" class="p p-first">The precise mechanism of
HIV-associated dyslipidemia remains elusive [<a href="#R9" rid="R9"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744561">9</a>]. Whether the dyslipidemia is a consequence
of HIV itself, its resultant inflammation, or the adverse effects
of medications, the fact remains that dyslipidemia is a common
finding in HIV-infected individuals that warrants therapy.
Interestingly, even in this study, the short-course administration
of nelfinavir in healthy HIV-seronegative subjects was associated
with a 105 mg/l median increase in LDL.</p>
<p id="P20">Pravastatin has become the preferred statin because of
its lack of significant metabolism by P4503A4 and results from
studies suggesting that pravastatin is safe and tolerable in
patients taking potent antiretroviral therapy [<a href="#R10" rid=
"R10" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744557">10</a>]. In our previous study, we demonstrated
that ritonavir/saquinavir decreased the pravastatin median AUC by
50% [<a href="#R2" rid="R2" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744564">2</a>]. In this study, NFV administration to
steady state reduced the exposure to pravastatin by a median of
46.5%. Similarly, we have also demonstrated that efavirenz reduces
the AUC of pravastatin [<a href="#R4" rid="R4" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_310856343">4</a>].This reduction in exposure may compromise
the effectiveness of pravastatin in patients taking certain PI
drugs or efavirenz. Although our study was not adequately powered
nor designed to evaluate pravastatin's effectiveness in lowering
LDL, we did note a trend suggesting that its effectiveness was
reduced.</p>
<p id="P21">The mechanism by which pravastatin concentrations are
reduced is not known. The metabolism of pravastatin is complex.
Induction of non-CYP3A4 oxidation or glucuronidation may result in
more rapid clearance of pravastatin. In addition, hepatic
transporter OATP1B1 may participate in increased drug elimination
[<a href="#R11" rid="R11" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744570">11</a>–<a href="#R13" rid="R13" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744569">13</a>]. Rifampin, which induces both CYP
isoforms as well as some transporters, reduced pravastatin exposure
by a mean of 30% without affecting <em>C</em><sub>max</sub>
[<a href="#R14" rid="R14" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744571">14</a>]. However, the CYP3A4 inhibitors
itraconazole and mibefradil had no significant effect on
pravastatin AUC [<a href="#R15" rid="R15" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744559">15</a>]. Gemfibrozil as well as ciclosporin have
been shown to increase pravastatin exposure during concomitant
administration, pointing to probable involvement of hepatic
transporters in this drug–drug interaction [<a href="#R16" rid=
"R16" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744573">16</a>,<a href="#R17" rid="R17" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744568">17</a>]. Regardless of the mechanism, the
implication is that effectiveness of pravastatin may be
reduced.</p>
<p id="P22">Clinical studies of pravastatin for the treatment of
HIV-associated dyslipidemia have shown mixed results. For example,
in a randomized trial of pravastatin versus fenofibrate for
combined HIV-associated dyslipidemia, only 36% of subjects
receiving 40 mg pravastatin daily met the LDL goal (median 20%
decrease) and 18% met the triglyceride goal (median 13% decrease)
by week 12 [<a href="#R18" rid="R18" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744558">18</a>]. In contrast, in a randomized, open-label
study comparing lipid-lowering therapy (pravastatin or bezafibrate)
with a switch from PI drug to non-nucleoside reverse transcriptase
inhibitors, Calza and colleagues [<a href="#R19" rid="R19" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744575">19</a>] reported reductions in total cholesterol,
LDL, and triglycerides of 45.8%, 39.5%, and 41.2%, respectively,
after 20 mg pravastatin daily for 12 months. Interestingly, 55% of
subjects receiving pravastatin had normal total cholesterol at 12
months. Benesic and colleagues [<a href="#R20" rid="R20" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_142744565">20</a>] reported results for patients treated
with pravastatin or fluvastatin. In 13 pravastatin-treated subjects
(11 taking 10 mg pravastatin), a decrease in total cholesterol
levels (from 7.12 to 6.29 mmol/l) after 12 weeks of therapy was
reported. The reduction of LDL level was only 14.4% in the
pravastatin group, without a significant reduction in
triglycerides. None of these studies was specifically analyzed by
the PI used to determine whether responses varied with specific PI
drugs. It is also possible that dosing differences, adherence, or
other factors may account for variations in efficacy reported.</p>
<p id="P23" class="p p-last">In summary, pravastatin remains the
statin of choice in HIV-infected persons taking antiretroviral
therapy, given its safety profile compared with simvastatin and
atorvastatin. The observed near 50% reduction in the pravastatin
median AUC and a trend toward less reduction in LDL when
coadministered with NFV suggest that higher doses of pravastatin
may need to be prescribed to achieve optimal lipid-lowering
activity. It remains unclear what the optimal dose of pravastatin
is to achieve maximal lipid-lowering activity safely in
HIV-infected individuals taking antiretroviral therapy. It is also
possible that greater improvements in lipid levels may be observed
if pravastatin doses are adjusted in the setting of agents that are
known to induce reductions in concentrations. Further studies
exploring the safety, tolerability, and efficacy of higher doses of
pravastatin are warranted.</p>
</div>
<div id="S9" class="tsec sec">
<h2 class="head no_bottom_margin" id="S9title">
Acknowledgements</h2>
<div class="sec">
<p id="__p1">The ACTG A5108 team would like to thank the volunteers
for participating in this study. Special thanks to F. Aweeka, M.
Becker, W. J. Burning, R. Christensen, R. DiFrancesco, E. Ferguson,
W. K. Henry, H. Meyers, S. I. Owens, M. Royal, J. Staggers, R.
Strada, S. Valle, and, M. J. Werder for their invaluable
assistance.</p>
</div>
</div>
<div id="APP1" class="tsec sec">
<h2 class="head no_bottom_margin" id="APP1title">Appendix</h2>
<!--/article/back/app-group/app/-->
<p id="P24">Participating ACTG A5108 NFV-pravastatin investigators
and sites: J. Norris, S. Valle (Stanford University); T. Powell, D.
Daria (University of Cincinnati); and J. Reid, R. Reichman
(University of Rochester Medical Center).</p>
</div>
<div id="__fn-groupid408841" class="tsec sec">
<h2 class="head no_bottom_margin" id="__fn-groupid408841title">
Footnotes</h2>
<!--back/fn-group-->
<div class="fm-sec half_rhythm small">
<p class="fn sec" id="FN2"></p>
<p id="P25" class="p p-first-last">Sponsorship: This study was
supported by the National Institute of Allergy and Infectious
Diseases: AI-38858 to the AIDS Clinical Trials Group, AI-25897 to
the University of Cincinnati, AI-27666 to Stanford University,
AI-27658 to the University of Rochester Medical Center, AI-27665 to
New York University, AI-32770 to the University of Colorado Health
Sciences Center, and AI-38855 to the SDAC/Harvard School of Public
Health. Additional support provided by Stanford University GCRC
grant M01-RR00070 and University of Rochester Medical Center GCRC
grant 5-M01-RR0044. Funded in part by Bristol-Myers Squibb Inc. and
Pfizer Pharmaceutical.</p>
<p class="fn sec" id="FN3"></p>
<p id="P26" class="p p-first-last"><em>Note: The results in this
study were presented in part at the</em> Second International AIDS
Society Conference on HIV Pathogenesis and Treatment. <em>Paris,
July 2003.</em></p>
</div>
</div>
<div id="__ref-listid408870" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid408870title">
References</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="R1">1. <span class=
"citation">Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on
its use in HIV infection. <span><span class=
"ref-journal">Drugs.</span> 2000;<span class=
"ref-vol">59</span>:581–620.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10776836" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R2">2. <span class=
"citation">Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg
JA, Blaschke T, for the ACTG 5047 Study Team Pharmacokinetic
interactions between protease inhibitors and statins in HIV
seronegative volunteers: ACTG Study A5047. <span><span class=
"ref-journal">AIDS.</span> 2002;<span class=
"ref-vol">16</span>:569–577.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11873000" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R3">3. <span class=
"citation">Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH,
Kerr BM. Pharmacokinetic interactions between nelfinavir and
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
atorvastatin and simvastatin. <span><span class=
"ref-journal">Antimicrob Agents Chemother.</span> 2001;<span class=
"ref-vol">45</span>:3445–3450.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC90851/">PMC free article</a>]</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11709322" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R4">4. <span class=
"citation">Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang
A, Alston BL, et al. Effect of efavirenz on the pharmacokinetics of
simvastatin, atorvastatin, and pravastatin: results of AIDS
Clinical Trials Group 5108 Study. <span><span class="ref-journal">J
Acquir Immun Defic Syndr.</span> 2005;<span class=
"ref-vol">39</span>:307–312.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15980690" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R5">5. <span class=
"citation">Yeh KC, Kwan KC. A comparison of numerical integrating
algorithms by trapezoidal, Lagrange, and spline approximation.
<span><span class="ref-journal">J Pharmacokinet Biopharm.</span>
1978;<span class="ref-vol">6</span>:79–98.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/650423" target="pmc_ext" ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R6">6. <span class=
"citation">Bergmann R, Ludbrook J, Spooren WPJM. Different outcomes
of the Wilcoxon–Mann–Whitney test from different statistics
packages. <span><span class="ref-journal">Am Stat.</span>
2000;<span class="ref-vol">54</span>:72–77.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R7">7. <span class=
"citation">Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis
associated with hydroxymethylglutaryl-coenzyme A reductase
inhibitors. <span><span class="ref-journal">Am Heart J.</span>
2004;<span class="ref-vol">147</span>:956–965.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15199341" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R8">8. <span class=
"citation">Center for Drug Evaluation and Research . <span class=
"ref-journal">Statistical Approaches to Establishing
Bioequivalence.</span> US Department of Health and Human Services,
Food and Drug Administration; Washington, DC: 2001. FDA Guidance
for Industry.</span></div>
<div class="ref-cit-blk half_rhythm" id="R9">9. <span class=
"citation">Cespedes MS, Aberg JA. Cardiovascular and endothelial
disease in HIV infection. <span><span class="ref-journal">Curr
Infect Dis Rep.</span> 2005;<span class=
"ref-vol">7</span>:309–315.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15963333" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R10">10. <span class=
"citation">Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG,
Tashima KT, et al. Guidelines for the evaluation and management of
dyslipidemia in human immunodeficiency virus (HIV)–infected adults
receiving antiretroviral therapy: recommendations of the HIV
Medical Association of the Infectious Disease Society of America
and the Adult AIDS Clinical Trials Group. <span><span class=
"ref-journal">Clin Infect Dis.</span> 2003;<span class=
"ref-vol">37</span>:613–627.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12942391" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R11">11. <span class=
"citation">Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA,
Brown CD, et al. Rosuvastatin pharmacokinectics in heart transplant
recipients administered an antirejection regimen including
cyclosporine. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 2004;<span class="ref-vol">76</span>:167–177.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/15289793" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R12">12. <span class=
"citation">Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K,
Hirota T, et al. Polymorphism of OATP-C (SLC21A6) and OAT3
(SLC22A8) genes: Consequences for pravastatin pharmacokinetics.
<span><span class="ref-journal">Clin Pharmacol Ther.</span>
2003;<span class="ref-vol">73</span>:554–565.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12811365" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R13">13. <span class=
"citation">Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, et al.
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics
of pitavastatin in healthy volunteers. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 2005;<span class=
"ref-vol">78</span>:342–350.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/16198653" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R14">14. <span class=
"citation">Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Effect
of rifampicin on pravastatin pharmacokinetics in healthy subjects.
<span><span class="ref-journal">Br J Clin Pharmacol.</span>
2004;<span class="ref-vol">57</span>:181–187.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1884432/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/14748817" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R15">15. <span class=
"citation">Jacobson TA. Comparative pharmacokinetic interaction
profiles of pravastatin, simvastatin, and atorvastatin when
coadministered with cytochrome P450 inhibitors. <span><span class=
"ref-journal">Am J Cardiol.</span> 2004;<span class=
"ref-vol">94</span>:1140–1146.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15518608" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R16">16. <span class=
"citation">Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ.
Gemfibrozil increases plasma pravastatin concentrations and reduces
pravastatin renal clearance. <span><span class="ref-journal">Clin
Pharmacol Ther.</span> 2003;<span class=
"ref-vol">73</span>:538–544.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12811363" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R17">17. <span class=
"citation">Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C,
Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin
in pediatric and adolescent cardiac transplant recipients on a
regimen of triple immunosuppression. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 2004;<span class=
"ref-vol">75</span>:101–109.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/14749696" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R18">18. <span class=
"citation">Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL,
Henry WK, for the ACTG 5087 team A randomized trial comparing the
efficacy and safety of fenofibrate versus pravastatin in
HIV-infected subjects with lipid abnormalities: AIDS Clinical
Trials Group Study 5087. <span><span class="ref-journal">AIDS Res
Hum Retroviruses.</span> 2005;<span class=
"ref-vol">21</span>:757–767.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/16218799" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R19">19. <span class=
"citation">Calza L, Manfredi R, Colangeli V, Tampellini L,
Sebastiani T, Pocaterra D, et al. Substitution of nevirapine or
efavirenz for protease inhibitor versus lipid-lowering therapy for
the management of dyslipidaemia. <span><span class=
"ref-journal">AIDS.</span> 2005;<span class=
"ref-vol">19</span>:1051–1058.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15958836" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R20">20. <span class=
"citation">Benesic A, Zilly M, Kluge F, Weissbrich B, Winzer R,
Klinker H, et al. Lipid lowering therapy with fluvastatin and
pravastatin in patients with HIV infection and antiretroviral
therapy: comparison of efficacy and interaction with indinavir.
<span><span class="ref-journal">Infection.</span> 2004;<span class=
"ref-vol">32</span>:229–233.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15293079" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1459289&amp;issue-id=130964&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
</div>
</div>
</div>
<!--post-content--></div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC1459289/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC1459289/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC1459289/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC1459289/pdf/nihms-8950.pdf">PDF
(34K)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC1459289" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1459289%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1459289%2F&amp;text=Pharmacokinetic%20interaction%20between%20nelfinavir%20and%20pravastatin%20in%20HIV-seronegative%20volunteers%3A%20ACTG%20Study%20A5108">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1459289%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="16514303" data-aiid="1459289"
data-aid="1459289" data-iid="130964" data-domainid="319"
data-domain="nihpa" data-accid="PMC1459289" data-md5=
"3f03dc2cc1f947b07c7d8c230b60f16c"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-16T15:42:38-04:00&amp;Host=ptpmc202">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC1459289/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- F4FC2520763012E1_0242SID /projects/PMC/PMCViewer@4.35 ptpmc202 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
